Detalimogene demonstrates 71% complete response rate at any time in preliminary analysis of legend pivotal cohort

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously eg-70) is in an ongoing pivotal study in patients with high-risk, bacillus calmette-guÉrin (bcg)-unresponsive, non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis). today, the company announced preliminary data from 21.
ENGN Ratings Summary
ENGN Quant Ranking